{
"id":"mk19_bb_gm_s32",
"subspecialtyId":"gm",
"title":"Breast Cancer Prevention and Screening",
"jsonContent":{
"type":"section",
"id":"mk19_bb_gm_s32",
"title":{
"__html":"Breast Cancer Prevention and Screening"
},
"titleNode":{
"type":"section-title",
"hlId":"e9f985",
"children":[
"Breast Cancer Prevention and Screening"
]
},
"children":[
{
"type":"section",
"id":"mk19_bb_gm_s32_1",
"title":{
"__html":"Prevention"
},
"titleNode":{
"type":"section-title",
"hlId":"c53b76",
"children":[
"Prevention"
]
},
"children":[
{
"type":"p",
"hlId":"af0839",
"children":[
"The ",
{
"type":"abbreviation",
"title":"U.S. Preventive Services Task Force",
"children":[
"USPSTF"
]
},
" recommends the following prevention for women aged >35 years with an increased risk for breast cancer (e.g., â‰¥3% risk in the next 5 years) and low risk for adverse medication effects:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"8e745e",
"children":[
"tamoxifen before menopause"
]
},
" ",
{
"type":"list-item",
"hlId":"65c084",
"children":[
"tamoxifen and raloxifene, or exemestane after menopause"
]
},
" "
]
},
{
"type":"p",
"hlId":"b9004d",
"children":[
"The USPSTF recommends that women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with breast cancer susceptibility 1 and 2 (",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA1/2"
]
},
") gene mutations be evaluated with an appropriate brief familial risk assessment tool. Women with a positive result on the risk assessment tool should receive genetic counseling and, if indicated after counseling, genetic testing."
]
}
]
},
{
"type":"section",
"id":"mk19_bb_gm_s32_2",
"title":{
"__html":"Screening"
},
"titleNode":{
"type":"section-title",
"hlId":"db7551",
"children":[
"Screening"
]
},
"children":[
{
"type":"p",
"hlId":"282091",
"children":[
"Screening recommendations vary. The USPSTF recommends biennial screening mammography for average-risk women beginning at age 50 years. Individualize screening decisions in women aged 75 or older based on breast cancer risk, overall prognosis and comorbid conditions, and personal patient preferences."
]
}
]
}
]
},
"tablesContent":{
}
}